Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesHCW Biologics Inc

HCW Biologics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.86 USD -0.08 ( 8.51%)
Last update at 2026-11-11T21:00:00Z
VOLUME
35538
Market Cap
41.98M

Momentum Score

…

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. The company was incorporated in 2018 and is headquartered in Miramar, Florida.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.86
Low
1.00
High
52 Week Price Range
0.91
Low
2.32
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.94
Dividend Yield
-
Revenue TTM
3.93M
Revenue Per Share
0.11
Gross Profit TTM
4.10M
Debt / Equity
0.48
ROE
-132.46%
Net Debt
2.86M
ROCE
-76.29%
Diluted EPS TTM
-0.76

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -14.90M -12.86M -5.80M -7.29M
Net income -14.72M -12.36M -5.78M -7.22M
Selling general administrative 8.33M 4.98M 2.44M 1.80M
Gross profit 2.59M - 4.10M -
Reconciled depreciation 0.72M 0.54M 0.60M 0.42M
Ebit -15.08M -13.37M -5.82M -7.37M
Ebitda -14.77M -12.82M -5.23M -6.94M
Depreciation and amortization 0.30M 0.54M 0.60M 0.42M
Operating income -15.08M -13.37M -5.82M -7.37M
Other operating expenses 21.80M 13.37M 9.92M 7.37M
Interest expense 0.13M 0.51M 0.00M 0.00M
Interest income - 0.51M 0.02M 0.07M
Net interest income -0.13M 0.51M 0.02M 0.07M
Income tax expense -0.18M -0.51M -0.02M -0.07M
Total revenue 6.72M 0.00M 4.10M 0.00M
Total operating expenses 17.67M 13.37M 9.92M 7.37M
Cost of revenue 4.14M - - -
Total other income expense net 0.18M 0.51M 0.02M 0.07M
Net income from continuing ops -15.21M -12.86M -5.80M -7.29M
Net income applicable to common shares -14.90M -12.86M -7.07M -7.78M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 28.51M 46.81M 53.51M 15.40M 10.07M
Other current assets 1.27M 0.20M 1.44M 0.65M 0.24M
Total liab 15.05M 9.38M 2.32M 1.00M 1.07M
Total stockholder equity 13.46M 37.43M 51.19M 14.40M 9.00M
Other current liab 2.43M 1.73M 2.10M 0.85M 0.67M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 31.12M 18.68M
Retained earnings -70.53M -45.54M -30.64M -16.72M -9.68M
Other assets - 0.33M 0.39M 0.03M 0.03M
Cash 3.60M 22.33M 11.73M 8.46M 7.36M
Total current liabilities 8.75M 2.96M 2.32M 1.00M 1.07M
Net debt 2.86M -15.92M -11.73M -8.46M -7.36M
Short term debt 0.15M 6.41M - - -
Short long term debt total 6.45M 6.41M - - -
Other stockholder equity 83.99M 82.96M 81.83M - -
Property plant equipment - 10.80M 1.12M 1.62M 2.00M
Total current assets 6.40M 34.07M 40.48M 12.15M 8.03M
Long term investments 1.60M 1.60M 11.52M 1.60M 0.00M
Net tangible assets - 37.43M 51.19M -16.72M -9.68M
Short term investments 0.00M 9.74M 24.98M - -
Net receivables 1.54M 0.42M 0.13M 2.50M 0.00M
Long term debt 6.30M 6.41M - - -
Inventory - 1.39M 2.20M 0.54M -
Accounts payable 6.17M 1.23M 0.22M 0.16M 0.39M
Accumulated other comprehensive income - - -53.51M - -
Common stock total equity - 0.00M - 0.00M 0.00M
Retained earnings total equity - -45.54M - - -
Non currrent assets other 0.06M 0.33M 0.39M 0.03M 0.03M
Non current assets total 22.11M 12.74M 13.03M 3.25M 2.04M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 24.98M -34.97M -0.19M -1.46M
Change to liabilities 0.42M 1.89M -0.63M 0.77M
Total cashflows from investing activities 14.71M -35.02M -0.19M -1.46M
Net borrowings 6.45M 6.45M 0.56M 0.56M
Total cash from financing activities 6.27M 49.27M 11.72M 13.45M
Change to operating activities 2.35M -2.80M -2.12M -0.66M
Net income -14.90M -12.86M -5.80M -7.29M
Change in cash 10.60M 3.27M 1.10M 5.22M
Begin period cash flow 11.73M 8.46M 7.36M 2.13M
End period cash flow 22.33M 11.73M 8.46M 7.36M
Total cash from operating activities -10.39M -10.98M -10.43M -6.77M
Issuance of capital stock 0.02M 56.03M 11.15M 13.45M
Depreciation 0.72M 0.54M 0.60M 0.42M
Other cashflows from investing activities - - - 0.00M
Dividends paid - 2.82M - -
Change to account receivables -0.28M 2.37M -2.50M -2.50M
Sale purchase of stock -0.17M - - -
Other cashflows from financing activities 6.26M -3.94M 11.71M 13.39M
Change to netincome 1.31M -0.14M 0.02M 0.00M
Capital expenditures 10.28M 0.05M 0.19M 1.46M
Change receivables -0.28M - - -
Cash flows other operating 2.36M - - -
Cash and cash equivalents changes 10.60M - - -
Change in working capital 2.49M 1.46M -5.25M 0.10M
Stock based compensation 1.12M 0.36M 0.02M 0.00M
Other non cash items 0.19M 0.03M -9.43M -
Free cash flow -20.66M -11.02M -10.62M -8.23M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
HCWB
HCW Biologics Inc		 -0.08
8.51%		 0.86 - - 19.43 4.10 20.39 -2.46
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

HCW Biologics Inc

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. The company was incorporated in 2018 and is headquartered in Miramar, Florida.

2929 North Commerce Parkway, Miramar, FL, United States, 33025

954 842 2024

https://www.hcwbiologics.com

45

Name Title Year Born
Dr. Hing C. Wong Ph.D. Founder, CEO, Director & Sec. 1954
Ms. Rebecca Byam CPA, M.B.A. Chief Financial Officer 1956
Dr. Peter Rhode Ph.D. Chief Scientific Officer & VP of Clinical Operations 1958
Ms. Nicole Valdivieso Esq. VP of Legal Affairs NA
Ms. Raquel Diaz M.S. Director of HR NA
Mr. Lee D. Flowers Sr. VP of Bus. Devel. 1946
Ms. Raquel Diaz M.S. Director of Human Resources NA
Dr. Hing C. Wong Ph.D. Founder, CEO, Director & Secretary 1954
Ms. Nicole Valdivieso Esq. Vice President of Legal Affairs NA
Mr. Lee D. Flowers Senior Vice President of Business Development 1946

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…